Risk of liver disease in methotrexate treated patients
Carey, John J
MetadataShow full item record
This item's downloads: 0 (view details)
Cited 44 times in Scopus (view citations)
Conway, Richard; Carey, John J (2017). Risk of liver disease in methotrexate treated patients. World Journal of Hepatology 9 (26), 1092-1100
Methotrexate is the first line drug treatment for a number of rheumatic and non-rheumatic diseases. It is effective in controlling disease activity and preventing disease-related damage, and significantly cheaper than many alternatives. Use in rheumatoid arthritis infers a significant morbidity and mortality benefit. Methotrexate is generally well tolerated but can cause symptomatic adverse events. Multiple serious adverse events have been attributed to methotrexate, based largely on older reports using high or daily doses, and subsequent case reports and circumstantial evidence. The risk with modern dosing regimens: Lower doses, weekly schedules, and concomitant folic acid is less clear. Clarification and dissemination of the actual risk is crucial so appropriate judgements can be made for patients who may benefit from this treatment. Methotrexate has been associated with a range of liver related adverse events ranging from asymptomatic transaminase elevations to fibrosis and fatal hepatic necrosis. Concern over potential liver toxicity has resulted in treatment avoidance, cessation, or recommendations for investigations which may be costly, invasive and unwarranted. Modern laboratory monitoring of liver blood tests may also influence the risk of more serious complications. The majority of present day studies report an approximate doubling of the relative risk of elevated transaminases in methotrexate treated patients but no increased risk of symptomatic or severe liver related adverse events. In this article we will review the evidence around methotrexate and liver related adverse events.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Showing items related by title, author, creator and subject.
Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders Doyle, Karen M.; Kennedy, Donna; Gorman, Adrienne M.; Gupta, Sanjeev; Healy, Sandra J. M.; Samali, Afshin (Wiley-Blackwell, 2011-09-26)The stimuli for neuronal cell death in neurodegenerative disorders are multi-factorial and may include genetic predisposition, environmental factors, cellular stressors such as oxidative stress and free radical production, ...
Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling Gorman, Adrienne M. (Wiley-Blackwell, 2008-07-10)Neuronal cell death plays a role in many chronic neurodegenerative diseases with the loss of particular subsets of neurons. The loss of the neurons occurs during a period of many years, which can make the mode(s) of cell ...
Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease Amin, Hatem K.; El-Sayed, Mohamed-I Kotb; Leheta, Ola F. (Informa UK Limited, 2016-07-19)Glomerular filtration rate and/or creatinine are not accurate methods for renal failure prediction. This study tested homocysteine (Hcy) as a predictive and prognostic marker for end stage renal disease (ESRD). In total, ...